Your browser doesn't support javascript.
loading
Suboptimal glycemic control among subjects with diabetes mellitus in India: a subset analysis of cross-sectional wave-7 (2016) data from the International Diabetes Management Practices Study (IDMPS).
Ramachandran, Ambady; Jain, Sunil M; Mukherjee, Sagarika; Phatak, Sanjeev; Pitale, Shailesh; Singh, Shailendra K; Agrawal, Navneet; Majumdar, Anirban; Deshpande, Neeta; Jhulka, Sandeep; Minakshisundaram, Shunmugavelu; Chawla, Manoj; Lodha, Sailesh; Maheshwari, Anuj; Makkar, Brij Mohan; Rao, Sadashiva; Shah, Parag; Ghosh, Romik; Mohanasundaram, Senthilnathan; Menon, Shalini; Chodankar, Deepa; Kanade, Vaishali; Trivedi, Chirag.
  • Ramachandran A; Department of Diabetology, Dr. Ramachandran's Diabetes Hospital, No. 28, Marshall's Road, Egmore, Chennai 600 008, India.
  • Jain SM; Department of Endocrinology, TOTALL Diabetes Hormone Institute, Indore, India.
  • Mukherjee S; Department of Diabetology, Dr. Sagarika Mukherjee's Endocrinology Clinic, Kolkata, India.
  • Phatak S; Department of Diabetology, Vijayratna Diabetes Diagnosis and Treatment Centre, Ahmedabad, India.
  • Pitale S; Department of Diabetology, Pitale Diabetes and Hormone Centre, Nagpur, India.
  • Singh SK; Department of Diabetology, Dr. Shailendra Kumar Singh's Clinic, Varanasi, India.
  • Agrawal N; Department of Diabetology and Obesity, Diabetes, Obesity and Thyroid Centre, Gwalior, India.
  • Majumdar A; Department of Endocrinology, Anirban's Diabetes- Obesity-Thyroid & Hormone Clinic, Kolkata, India.
  • Deshpande N; Department of Diabetology, Belgaum Diabetes Centre, Belgaum.
  • Jhulka S; Department of Diabetology, Radiance the Hormone Health Clinic, Indore, India.
  • Minakshisundaram S; Department of Diabetology, Trichy Diabetes Speciality Centre (P) Ltd., Trichy, India.
  • Chawla M; Department of Diabetology, Lina Diabetes Care Centre and Mumbai Diabetes Research Centre, Mumbai, India.
  • Lodha S; Department of Endocrinology, Dr. Sailesh Lodha Clinic, Rajasthan, India.
  • Maheshwari A; Department of Diabetology, Shri Hari Kamal Diabetes and Research Clinic, Lucknow, India.
  • Makkar BM; Department of Diabetology and Obesity, Diabetes and Obesity Centre, New Delhi, India.
  • Rao S; Department of Diabetology, Diabetic Care Centre, Vijayawada, India.
  • Shah P; Department of Endocrinology, Gujarat Endocrine Centre, Ahmedabad, India.
  • Ghosh R; Medical Affairs, Sanofi India Limited, Mumbai, Maharashtra, India.
  • Mohanasundaram S; Medical Affairs, Sanofi India Limited, Mumbai, Maharashtra, India.
  • Menon S; Medical Affairs, Sanofi India Limited, Mumbai, Maharashtra, India.
  • Chodankar D; Clinical Study Unit, Sanofi Synthelabo India Limited, Mumbai, Maharashtra, India.
  • Kanade V; Clinical Study Unit, Sanofi Synthelabo India Limited, Mumbai, Maharashtra, India.
  • Trivedi C; Clinical Study Unit, Sanofi Synthelabo India Limited, Mumbai, Maharashtra, India.
Ther Adv Endocrinol Metab ; 11: 2042018820937217, 2020.
Article en En | MEDLINE | ID: mdl-32647562
ABSTRACT

OBJECTIVE:

To assess the real-world management practices of subjects with type 2 diabetes mellitus (T2DM) and type 1 diabetes mellitus (T1DM) in India.

METHODS:

This cross-sectional study was conducted between 7 March 2016 and 15 May 2016 in India as part of the seventh wave (2016) of the International Diabetes Management Practices Study (IDMPS). Adult subjects with T1DM or T2DM visiting physicians during a 2-week recruitment period were included.

RESULTS:

A total of 55 physicians included 539 subjects who met eligibility criteria. Of 495 subjects with T2DM, 303 were treated with oral glucose lowering drugs (OGLDs) only, 158 were treated with OGLD + insulin, and 27 received insulin only. Among 44 subjects with T1DM receiving insulin, 13 (29.5%) were also treated with OGLD therapy. The most commonly used insulin regimens were basal alone (69/184; 37.5%) and premixed alone (63/184; 34.2%) in subjects with T2DM, and basal + prandial insulin (24/44; 54.5%) in subjects with T1DM. Proportions of subjects achieving glycemic targets were low [glycated haemoglobin (HbA1c) <7% T1DM = 7.3% (3/44), T2DM = 25.2% (106/495); as targeted by the treating physician T1DM = 31.8% (14/44), T2DM = 32.1% (59/185); global target T1DM = 4.8% (2/42) and T2DM = 1.7% (8/482)]. In subjects with T2DM, HbA1c <7% was noted in 11/22 subjects receiving insulin only and 76/260 receiving only OGLDs. Lack of experience in self-managing insulin dosing, poor diabetes education and failure to titrate insulin dosages were the main reasons for non-achievement of glycemic targets.

CONCLUSION:

Timely insulinization, education and empowerment of people with diabetes may help improve glycemic control in India.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Prevalence_studies Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Prevalence_studies Idioma: En Año: 2020 Tipo del documento: Article